{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:57:20Z","timestamp":1790895440352,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["20316943"],"award-info":[{"award-number":["20316943"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recent clinical reports indicate a correlation between new-onset and relapse of nephrotic syndrome (NS) following coronavirus 2019 (COVID-19) vaccination in patients with glomerular diseases. However, there are no reports of a nationwide survey on NS following COVID-19 vaccination in Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a web-based survey of council members of the Japanese Society of Nephrology (581 members, 382 facilities) to elucidate the relationship between COVID-19 vaccination and new-onset and relapse of NS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Following COVID-19 vaccination, 27 patients (male: 15, 55.6%) with new-onset (<jats:italic>n<\/jats:italic>\u2009=\u20096) and relapse (<jats:italic>n<\/jats:italic>\u2009=\u200921) of NS were reported. Of them, 12 (44.4%) patients were diagnosed with minimal change disease at the occurrence of NS. Five patients developed a slight increase in serum creatinine levels; however, none progressed to severe renal dysfunction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings clarify the clinical features of new-onset and relapse of NS following COVID-19 vaccination. Although there was no obvious progression to severe renal dysfunction, clinicians and pathologists should be aware that NS is a potential adverse effect of the vaccines.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10157-022-02231-y","type":"journal-article","created":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T15:03:05Z","timestamp":1652626985000},"page":"909-916","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["New-onset and relapse of nephrotic syndrome following COVID-19 vaccination: a questionnaire survey in Japan"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5398-3667","authenticated-orcid":false,"given":"Naoki","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,15]]},"reference":[{"key":"2231_CR1","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41586-021-04188-6","volume":"600","author":"J Li","year":"2021","unstructured":"Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity and global spread of SARS-CoV-2. Nature. 2021;600:408\u201318.","journal-title":"Nature"},{"key":"2231_CR2","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s10157-021-02082-z","volume":"25","author":"Y Sugawara","year":"2021","unstructured":"Sugawara Y, Iwagami M, Yoshida Y, Kikuchi K, Ando R, Shinoda T, et al. Nationwide survey of the coronavirus disease 2019 prevention and treatment systems for kidney disease patients: a study of Japanese Society of Nephrology-certified educational facilities. Clin Exp Nephrol. 2021;25:996\u20131002.","journal-title":"Clin Exp Nephrol"},{"key":"2231_CR3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"2231_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403\u201316.","journal-title":"N Engl J Med"},{"key":"2231_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99\u2013111.","journal-title":"Lancet"},{"key":"2231_CR6","unstructured":"Official Website of the Prime Minister of Japan and His cabinet, Total number of vaccine doses administered to date (2022). https:\/\/japan.kantei.go.jp\/ongoingtopics\/vaccine.html. Accessed 11 Mar 2022."},{"key":"2231_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","volume":"144","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144:471\u201384.","journal-title":"Circulation"},{"key":"2231_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.kint.2021.04.035","volume":"100","author":"VD D'Agati","year":"2021","unstructured":"D\u2019Agati VD, Kudose S, Bomback AS, Adamidis A, Tartini A. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine. Kidney Int. 2021;100:461\u20133.","journal-title":"Kidney Int"},{"key":"2231_CR9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1053\/j.ajkd.2021.06.008","volume":"78","author":"S Leclerc","year":"2021","unstructured":"Leclerc S, Royal V, Lamarche C, Laurin LP. Minimal change disease with severe acute kidney injury following the Oxford-AstraZeneca COVID-19 vaccine: a case report. Am J Kidney Dis. 2021;78:607\u201310.","journal-title":"Am J Kidney Dis"},{"key":"2231_CR10","doi-asserted-by":"publisher","first-page":"205435812110582","DOI":"10.1177\/20543581211058271","volume":"8","author":"J Hanna","year":"2021","unstructured":"Hanna J, Ingram A, Shao T. Minimal change disease after first dose of Pfizer-BioNTech COVID-19 vaccine: a case report and review of minimal change disease related to COVID-19 vaccine. Can J Kidney Health Dis. 2021;8:20543581211058270.","journal-title":"Can J Kidney Health Dis"},{"key":"2231_CR11","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1093\/ckj\/sfab155","volume":"14","author":"S Unver","year":"2021","unstructured":"Unver S, Haholu A, Yildirim S. Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine. Clin Kidney J. 2021;14:2608\u201311.","journal-title":"Clin Kidney J"},{"key":"2231_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12882-021-02583-9","volume":"22","author":"S Thappy","year":"2021","unstructured":"Thappy S, Thalappil SR, Abbarh S, Al-Mashdali A, Akhtar M, Alkadi MM. Minimal change disease following the Moderna COVID-19 vaccine: first case report. BMC Nephrol. 2021;22:376.","journal-title":"BMC Nephrol"},{"key":"2231_CR13","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1093\/ckj\/sfab156","volume":"14","author":"S Kobayashi","year":"2021","unstructured":"Kobayashi S, Fugo K, Yamazaki K, Terawaki H. Minimal change disease soon after Pfizer-BioNTech COVID-19 vaccination. Clin Kidney J. 2021;14:2606\u20137.","journal-title":"Clin Kidney J"},{"key":"2231_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1053\/j.ajkd.2021.05.006","volume":"78","author":"H Komaba","year":"2021","unstructured":"Komaba H, Wada T, Fukagawa M. Relapse of minimal change disease following the Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis. 2021;78:469\u201370.","journal-title":"Am J Kidney Dis"},{"key":"2231_CR15","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.kint.2021.03.002","volume":"99","author":"L Negrea","year":"2021","unstructured":"Negrea L, Rovin BH. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy. Kidney Int. 2021;99:1487.","journal-title":"Kidney Int"},{"key":"2231_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-021-00679-7","author":"M Okada","year":"2022","unstructured":"Okada M, Kikuchi E, Nagasawa M, Oshiba A, Shimoda M. An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine. CEN Case Rep. 2022. https:\/\/doi.org\/10.1007\/s13730-021-00679-7.","journal-title":"CEN Case Rep"},{"key":"2231_CR17","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.kint.2021.06.011","volume":"100","author":"S Kudose","year":"2021","unstructured":"Kudose S, Friedmann P, Albajrami O, D\u2019Agati VD. Histologic correlates of gross hematuria following Moderna COVID-19 vaccine in patients with IgA nephropathy. Kidney Int. 2021;100:468\u20139.","journal-title":"Kidney Int"},{"key":"2231_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-021-00677-9","author":"S Nakatani","year":"2022","unstructured":"Nakatani S, Mori K, Morioka F, Hirata C, Tsuda A, Uedono H, et al. New-onset kidney biopsy-proven IgA vasculitis after receiving mRNA-1273 COVID-19 vaccine: case report. CEN Case Rep. 2022. https:\/\/doi.org\/10.1007\/s13730-021-00677-9.","journal-title":"CEN Case Rep"},{"issue":"4","key":"2231_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s10157-021-02157-x","volume":"26","author":"K Matsuzaki","year":"2021","unstructured":"Matsuzaki K, Aoki R, Nihei Y, Suzuki H, Kihara M, Yokoo T, et al. Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan. Clin Exp Nephrol. 2021;26(4):316\u201322.","journal-title":"Clin Exp Nephrol"},{"issue":"11","key":"2231_CR20","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.34067\/KID.0005372021","volume":"2","author":"TN Caza","year":"2021","unstructured":"Caza TN, Cassol CA, Messias N, Hannoudi A, Haun RS, Walker PD, et al. Glomerular disease in temporal association with SARS-CoV-2 vaccination: a series of 29 case. Kidney360. 2021;2(11):1770\u201380.","journal-title":"Kidney360"},{"key":"2231_CR21","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586:594\u20139.","journal-title":"Nature"},{"key":"2231_CR22","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2\u2013Preliminary Report. N Engl J Med. 2020;383:1920\u201331.","journal-title":"N Engl J Med"},{"key":"2231_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","volume":"27","author":"KJ Ewer","year":"2021","unstructured":"Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial. Nat Med. 2021;27:270\u20138.","journal-title":"Nat Med"},{"key":"2231_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.ajkd.2021.06.004","volume":"78","author":"as bomback","year":"2021","unstructured":"bomback as, kudose s, d\u2019agati vd. De novo and relapsing glomerular diseases after COVID-19 vaccination: what do we know so far? Am J Kidney Dis. 2021;78:477\u201380.","journal-title":"Am J Kidney Dis"},{"key":"2231_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257397","volume":"16","author":"N Nakagawa","year":"2021","unstructured":"Nakagawa N, Mizuno M, Kato S, Maruyama S, Sato H, Nakaya I, et al. Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: a retrospective analysis of data from the Japan Renal Biopsy Registry. PLoS ONE. 2021;16: e0257397.","journal-title":"PLoS ONE"},{"key":"2231_CR26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.ekir.2020.06.013","volume":"5","author":"SY Robbins-Juarez","year":"2020","unstructured":"Robbins-Juarez SY, Qian L, King KL, Stevens JS, Husain SA, Radhakrishnan J, et al. Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis. Kidney Int Rep. 2020;5:1149\u201360.","journal-title":"Kidney Int Rep"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-022-02231-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-022-02231-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-022-02231-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T04:16:33Z","timestamp":1660709793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-022-02231-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,15]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2231"],"URL":"https:\/\/doi.org\/10.1007\/s10157-022-02231-y","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,15]]},"assertion":[{"value":"12 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}